These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15810907)

  • 21. Difficult clinical challenges in haemophilia: international experiential perspectives.
    Forsyth AL; Giangrande P; Hay CR; Kenet G; Kessler CM; Knöbl PN; Llinás A; Santagostino E; Young G
    Haemophilia; 2012 Jul; 18 Suppl 5():39-45. PubMed ID: 22757683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Forum on: the role of recombinant factor VIII in children with severe haemophilia A.
    Franchini M; Coppola A; Molinari AC; Santoro C; Schinco P; Speciale V; Tagliaferri A
    Haemophilia; 2009 Mar; 15(2):578-86. PubMed ID: 19187188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discontinuing early prophylaxis in severe haemophilia leads to deterioration of joint status despite low bleeding rates.
    Nijdam A; Foppen W; De Kleijn P; Mauser-Bunschoten EP; Roosendaal G; van Galen KP; Schutgens RE; van der Schouw YT; Fischer K
    Thromb Haemost; 2016 May; 115(5):931-8. PubMed ID: 26791021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.
    Manco-Johnson MJ; Abshire TC; Shapiro AD; Riske B; Hacker MR; Kilcoyne R; Ingram JD; Manco-Johnson ML; Funk S; Jacobson L; Valentino LA; Hoots WK; Buchanan GR; DiMichele D; Recht M; Brown D; Leissinger C; Bleak S; Cohen A; Mathew P; Matsunaga A; Medeiros D; Nugent D; Thomas GA; Thompson AA; McRedmond K; Soucie JM; Austin H; Evatt BL
    N Engl J Med; 2007 Aug; 357(6):535-44. PubMed ID: 17687129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
    Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
    Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose and outcome of care in haemophilia--how do we define cost-effectiveness?
    Fischer K; Van den Berg HM; Thomas R; Kumar S; Poonnoose P; Viswabandya A; Mathews V; Kavitha ML; Bhattacharji S; Srivastava A
    Haemophilia; 2004 Oct; 10 Suppl 4():216-20. PubMed ID: 15479401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Haemophilia care in children--benefits of early prophylaxis for inhibitor prevention.
    Mancuso ME; Graca L; Auerswald G; Santagostino E
    Haemophilia; 2009 Jan; 15 Suppl 1():8-14. PubMed ID: 19125935
    [TBL] [Abstract][Full Text] [Related]  

  • 28. To bleed or not to bleed - is that a question?
    Aledort LM
    J Thromb Haemost; 2010 Jan; 8(1):81-2. PubMed ID: 19874456
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparing prophylaxis with episodic treatment in haemophilia A: implications for clinical practice.
    Manco-Johnson M
    Haemophilia; 2007 Sep; 13 Suppl 2():4-9. PubMed ID: 17685917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Towards the goal of prophylaxis: experience and treatment strategies from Sweden, France and Hungary.
    Petrini P; Chambost H; Nemes L
    Haemophilia; 2004 Oct; 10 Suppl 4():94-6. PubMed ID: 15479379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
    Ahnström J; Berntorp E; Lindvall K; Björkman S
    Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan.
    Taki M; Shirahata A
    Haemophilia; 2009 Jan; 15(1):78-82. PubMed ID: 18700841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prophylaxis therapy in paediatric patients with haemophilia: a survey of clinical management trends in Italy.
    Castaman G; Rocino A; Mazzucconi MG; Zanon E; Gagliano F; Molinari AC
    Blood Transfus; 2015 Oct; 13(4):631-8. PubMed ID: 26057481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hemophilia and prophylaxis.
    Ljung R
    Pediatr Blood Cancer; 2013; 60 Suppl 1():S23-6. PubMed ID: 23109472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Devising a best practice approach to prophylaxis in boys with severe haemophilia: evaluation of current treatment strategies.
    Carcao M; Chambost H; Ljung R
    Haemophilia; 2010 Mar; 16 Suppl 2():4-9. PubMed ID: 20132332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between factor VIII replacement therapy and joint damage in severe haemophilia.
    Lowe GD
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S3-5. PubMed ID: 9351528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prophylaxis in haemophilia patients with inhibitors.
    Leissinger CA
    Haemophilia; 2006 Dec; 12 Suppl 6():67-72; discussion 72-3. PubMed ID: 17123397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Experiences in the prevention of arthropathy in haemophila patients with inhibitors.
    Jimenez-Yuste V; Rodriguez-Merchan EC; Alvarez MT; Quintana M; Martin-Salces M; Hernandez-Navarro F
    Haemophilia; 2008 Nov; 14 Suppl 6():28-35. PubMed ID: 19134031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Some recent developments regarding arthropathy and inhibitors in haemophilia.
    Rodriguez-Merchan EC
    Haemophilia; 2008 Mar; 14(2):242-7. PubMed ID: 18201189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modelling lifelong effects of different prophylactic treatment strategies for severe haemophilia A.
    Fischer K; Lewandowski D; Janssen MP
    Haemophilia; 2016 Sep; 22(5):e375-82. PubMed ID: 27353496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.